glp-1r agonist 1

GLP-1R agonist 1, a thickened imidazole derivative, is a potent agonist of GLP-1R with potential applications in diabetes research.

GLP-1R agonist 10 is a GLP-1 agonist (EC50: 0.051 nM).

GLP-1R agonist 12 (Compound 123) is utilized in diabetes mellitus research as a glucagon-like peptide-1 receptor (GLP-1R) agonist.

GLP-1R agonist 17 is a potent GLP-1 receptor agonist with excellent efficacy in activating the GLP-1 receptor, primarily used in cardiovascular metabolic disease research.

GLP-1R agonist 14, also known as Compound 14, is a potent agonist of the GLP-1 receptor, demonstrating an EC50 range of 0-20 nM against human GLP-1 [1].

GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist [1].

Compound 115a, a GLP-1R agonist, effectively activates the GLP-1 receptor with an EC50 of 0.15 nM [1].

GLP-1R agonist 18 (example 117) acts as an agonist at GLP-1R, exhibiting an EC50 of 0.044 nM [1].

GLP-1R agonist 19 (M3190) is a potent, selective GLP-1 receptor agonist that demonstrates excellent plasma and liver microsomal stability, along with low hERG toxicity [1].

GLP-1R Agonist DMB is an agonist of glucagon-like peptide 1 receptor (GLP-1R; KB = 26.3 nM for the recombinant human receptor).

Compound 1, also known as GLP-1R agonist 26, is an agonist of the glucagon-like peptide-1 receptor (GLP-1R) with an EC50 of <10 nM.

GLP-1R agonist 21 (Compound I-134) is an agonist of the glucagon-like peptide-1 receptor (GLP-1 receptor) with an EC50 of 0.0104 nM.

GLP-1R agonist 22 (Compound I-135) functions as an agonist for the glucagon-like peptide-1 receptor (GLP-1 receptor), with an EC50 of 0.0165 nM.

GLP-1R agonist 20 (Compound I-132) is an agonist of the glucagon-like peptide-1 receptor (GLP-1 receptor), with an EC50 value of 0.0162 nM.

GLP-1R agonist 31 (Compound 1) is an amorphous glucagon-like peptide-1 receptor (GLP-1R) agonist.

GLP-1R agonist 33 (Compound 224) is a GLP-1 receptor agonist with potential applications in research related to diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD).

GLP-1R agonist 34 (Compound 1) is an orally active small molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R). It enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, thereby effectively reducing blood glucose levels. GLP-1R agonist 34 holds potential for research into metabolic disorders such as type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

GLP-1R agonist 4, a potent agonist of GLP-1R, shows promise for diabetes research[1]. Acting on the principle of glucagon-like peptide-1 (GLP-1), a hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract, this compound holds potential therapeutic value.

GLP-1R/GIPR agonist-1 is a dual receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It mimics the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while suppressing glucagon release, thus lowering blood sugar. This compound is used in research related to metabolic disorders such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

GLP-1R/GIPR agonist-1 sodium is the sodium salt form of GLP-1R/GIPR agonist-1. It acts as a dual agonist for the glucagon-like peptide-1 receptor (GLP-1R, EC50 = 0.57 nM) and the glucose-dependent insulinotropic polypeptide receptor (GIPR, EC50 = 0.75 nM). GLP-1R/GIPR agonist-1 sodium lowers blood glucose by mimicking the effects of endogenous hormones GLP-1 and GIP, enhancing insulin secretion, and inhibiting glucagon secretion. This compound is applicable in research on metabolic disorders such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

GLP-1R agonist 25 (compound 13) is a GLP1-R agonist with an EC50 of 0.167 nM and is utilized in research for Type II diabetes.

GLP-1R agonist 27 (compound 21) is a potent and orally active GLP-1R agonist. It enhances the accumulation of cyclic adenosine monophosphate (cAMP), reduces blood glucose levels, and decreases food intake. GLP-1R agonist 27 shows potential for research in obesity and type 2 diabetes mellitus (T2DM).

GLP-1R agonist 28 (Compound 19) is an orally active GLP-1R agonist that enhances insulin secretion and is applicable for research into GLP-1R-related disorders.

GLP-1R agonist 29 (Compound 20) is a GLP-1R agonist that induces hGLP-1R-mediated cAMP stimulation with an EC50 of 0.018 nM. It exhibits favorable pharmacokinetic properties and shows good in vivo exposure, with an AUC0-∞,sc of 77688 ng·h/mL.